Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US11518772B2 · kind B2 · utility
1Cited by
142References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 18, 2020 |
| Grant date | Dec 6, 2022 |
| Priority date | — |
| Expiry date | Sep 18, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D491/107
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides certain fused tricyclic ring derivatives that are Src Homology-2 phosphatase (SHP2) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of SHP2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.